CD274 and neoplasm: In the exploratory analysis according to treatment subgroups, patients with high tumor PD-L1 expression (≥ 50%) by IHC who received single-agent pembrolizumab seemed to derive the most significant PFS benefit in the presence of high KRAS4A cmRNA levels.